IV 
117TH CONGRESS 
2D SESSION 
H. RES. 1287 
Of inquiry directing the President to provide certain documents in the Presi-
dent’s possession to the House of Representatives relating to the recall 
of infant formula manufactured by Abbott Laboratories and potential 
impacts on the infant formula supply chain. 
IN THE HOUSE OF REPRESENTATIVES 
JULY 26, 2022 
Mr. WALBERG submitted the following resolution; which was referred to the 
Committee on Energy and Commerce 
RESOLUTION 
Of inquiry directing the President to provide certain docu-
ments in the President’s possession to the House of 
Representatives relating to the recall of infant formula 
manufactured by Abbott Laboratories and potential im-
pacts on the infant formula supply chain. 
Resolved, That not later than 14 days after the adop-
tion of this resolution, the President is directed to furnish 
to the House of Representatives copies of any document 
or record, audio recording, memorandum, call log, cor-
respondence (electronic or otherwise), or other commu-
nication in the President’s possession (or any portion 
thereof), that refers or relates to the following: 
VerDate Sep 11 2014 
04:11 Jul 27, 2022
Jkt 029200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\HR1287.IH
HR1287
SSpencer on DSK126QN23PROD with BILLS
•HRES 1287 IH 
(1) the memoranda and report referenced in the 
testimony given by Dr. Robert Califf on May 25, 
2022, during the hearing related to the recall of in-
fant formula manufactured by Abbott Laboratories 
and potential impacts on the infant formula supply 
chain held by the Committee on Subcommittee on 
Oversight and Investigations of the Committee on 
Energy and Commerce of the House of Representa-
tives; 
(2) all communications between the Commis-
sioner of Food and Drugs and other staff of the 
Food and Drug Administration and the White 
House regarding the infant formula recall and po-
tential impact during or before February 2022; 
(3) the failure of the Food and Drug Adminis-
tration to ensure the whistleblower complaint sub-
mitted to the Food and Drug Administration by an 
employee of Abbott Laboratories was sent to all nec-
essary and appropriate officials and what actions the 
Food and Drug Administration has taken to prevent 
such a failure from happening in the future; 
(4) the number of full-time equivalent positions 
in the Office of Regulatory Affairs of the Food and 
Drug Administration that remain vacant for food 
safety compliance and inspection staff; 
VerDate Sep 11 2014 
03:49 Jul 27, 2022
Jkt 029200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\HR1287.IH
HR1287
SSpencer on DSK126QN23PROD with BILLS
•HRES 1287 IH 
(5) all communications between the Food and 
Drug Administration and the Department of Agri-
culture about the recall of infant formula manufac-
tured by Abbott Laboratories and the potential im-
pact on the Special Supplemental Nutrition Program 
for Women, Infants, and Children, including the 
timing of such communications; and 
(6) the number of submissions pending at the 
Food and Drug Administration as of the date of the 
adoption of this resolution for the marketing of in-
fant formula, delineated by domestic and foreign 
manufacturers. 
Æ 
VerDate Sep 11 2014 
03:49 Jul 27, 2022
Jkt 029200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6301
E:\BILLS\HR1287.IH
HR1287
SSpencer on DSK126QN23PROD with BILLS